Inhibitor of histone deacetylation, depsipeptide (FR901228), in the treatment of peripheral and cutaneous T-cell lymphoma: a case report
The DOI matches its Crossref record; 17 of the 17 references it cites were found in a registry or an index.
Abstract
Depsipeptide, FR901228, has demonstrated potent in vitro and in vivo cytotoxic activity against murine and human tumor cell lines. In the laboratory, it has been shown to be a histone deacetylase (HDAC) inhibitor. In a phase I trial of depsipeptide conducted at the National Cancer Institute, 3 patients with cutaneous T-cell lymphoma had a partial response, and 1 patient with peripheral T-cell lymphoma, unspecified, had a complete response. Sézary cells isolated from patients after treatment had increased histone acetylation. These results suggest that inhibition of HDAC is a novel and potentially effective therapy for patients with T-cell lymphoma.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Reporting results of cancer treatment
Miller, A. B., Hoogstraten, B., Staquet, M., & Winkler, A. (1981) · Cancer · doi:10.1002/1097-0142(19810101)47:1<207::aid-cncr2820470134>3.0.co;2-6 · Cited by 7,793
The Non-Hodgkin's Lymphoma Classification Project (1997) · Blood · doi:10.1182/blood.v89.11.3909 · Cited by 2,461
Willemze, R., Kerl, H., Sterry, W., Berti, E., Cerroni, L., Chimenti, M. S., Díaz-Pérez, J. L., Geerts, M., Goos, M., Knobler, R., et al. (1997) · PubMed · doi:10.1182/blood.v90.1.354 · Cited by 1,270
Histone deacetylases, transcriptional control, and cancer
Cress, W. D., & Seto, E. (2000) · Journal of Cellular Physiology · doi:10.1002/(sici)1097-4652(200007)184:1<1::aid-jcp1>3.0.co;2-7 · Cited by 621
Wang, J., Hoshino, T., Redner, R. L., Kajigaya, S., & Liu, J. M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.18.10860 · Cited by 512
UEDA, H., NAKAJIMA, H., HORI, Y., FUJITA, T., NISHIMURA, M., GOTO, T., & OKUHARA, M. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.301 · Cited by 489
FR901228, a Potent Antitumor Antibiotic, Is a Novel Histone Deacetylase Inhibitor
Nakajima, H., Kim, Y. B., Terano, H., Yoshida, M., & Horinouchi, S. (1998) · Experimental Cell Research · doi:10.1006/excr.1998.4027 · Cited by 487
Lee, J. S., Paull, K., Alvarez, M., Hose, C., Monks, A., Grever, M., Fojo, A. T., & Bates, S. E. (1994) · Molecular Pharmacology · doi:10.1016/s0026-895x(25)09793-7 · Cited by 336
Self-citationPrimary Cutaneous T-Cell Lymphoma: Review and Current Concepts
Siegel, R. S., Pandolfino, T., Guitart, J., Rosen, S., & Kuzel, T. M. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.15.2908 · Cited by 308
Sandor, V, Senderowicz, A., Mertins, S., Sackett, D., Sausville, E., Blagosklonny, M. V., & Bates, S. E. (2000) · British Journal of Cancer · doi:10.1054/bjoc.2000.1327 · Cited by 290
Self-citationUEDA, H., MANDA, T., MATSUMOTO, S., MUKUMOTO, S., NISHIGAKI, F., KAWAMURA, I., & SHIMOMURA, K. (1994) · The Journal of Antibiotics · doi:10.7164/antibiotics.47.315 · Cited by 257
Gemcitabine Treatment in Pretreated Cutaneous T-Cell Lymphoma: Experience in 44 Patients
Zinzani, P. L., Baliva, G., Magagnoli, M., Bendandi, M., Modugno, G., Gherlinzoni, F., Orcioni, G. F., Ascani, S., Simoni, R., Pileri, S. A., et al. (2000) · Journal of Clinical Oncology · doi:10.1200/jco.2000.18.13.2603 · Cited by 225
Systemic Therapy of Cutaneous T-Cell Lymphomas (Mycosis Fungoides and the Sezary Syndrome)
Bunn, P. A., Hoffman, S. J., Norris, D., Golitz, L. E., & Aeling, J. L. (1994) · Annals of Internal Medicine · doi:10.7326/0003-4819-121-8-199410150-00007 · Cited by 214
Chromatin Remodeling and Leukemia: New Therapeutic Paradigms
Redner, R. L., Wang, J., & Liu, J. M. (1999) · Blood · doi:10.1182/blood.v94.2.417 · Cited by 189
Ueda, H., Nakajima, H., Hori, Y., Goto, T., & Okuhara, M. (1994) · Bioscience, Biotechnology, and Biochemistry · doi:10.1271/bbb.58.1579 · Cited by 143
Koyama, Y., Adachi, M., Sekiya, M., Takekawa, M., & Imai, K. (2000) · Blood · doi:10.1182/blood.v96.4.1490 · Cited by 96
Fungal metabolite FR901228 inhibits c-Myc and Fas ligand expression
Wang, R., Brunner, T., Zhang, L., & Shi, Y. (1998) · Oncogene · doi:10.1038/sj.onc.1202059 · Cited by 66
Cited by
Histone deacetylases (HDACs): characterization of the classical HDAC family
RUIJTER, A. J. M. D., GENNIP, A. H. V., CARON, H. N., KEMP, S., & KUILENBURG, A. B. P. V. (2003) · Biochemical Journal · doi:10.1042/bj20021321 · Cited by 3,114
Histone deacetylase inhibitors and the promise of epigenetic (and more) treatments for cancer
Minucci, S., & Pelicci, P. G. (2006) · Nature Reviews Cancer · doi:10.1038/nrc1779 · Cited by 2,200
Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
Johnstone, R. W. (2002) · Nature Reviews Drug Discovery · doi:10.1038/nrd772 · Cited by 1,515
Das, P. M., & Singal, R. (2004) · Journal of Clinical Oncology · doi:10.1200/jco.2004.07.151 · Cited by 1,456
FDA Approval Summary: Vorinostat for Treatment of Advanced Primary Cutaneous T-Cell Lymphoma
Mann, B. S., Johnson, J. R., Cohen, M. H., Justice, R., & Pazdur, R. (2007) · The Oncologist · doi:10.1634/theoncologist.12-10-1247 · Cited by 1,365
Metadata
- Authors
- Piekarz, R. L., Robey, R., Sandor, V., Bakke, S., Wilson, W. H., Dahmoush, L., Kingma, D. M., Turner, M. L., Altemus, R., & Bates, S. E.
- Venue
- Blood
- Publisher
- American Society of Hematology
- Published
- 2001-11-01
- Volume
- 98
- Issue
- 9
- Pages
- 2865-2868
- ISSN
- 0006-4971 (ISSN-L)
- 1528-0020
- OpenAlex
- W2052181006
- Cited by
- 445
- References
- 17
- FWCI
- 27.55
- Type
- journal article
- Language
- en
- Open access
- closed
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.